Axsome Therapeutics Inc (AXSM)

Currency in USD
111.13
+1.92(+1.75%)
Closed·
109.00-2.13(-1.92%)
·

AXSM Earnings

Latest Release
Aug 04, 2025
EPS / Forecast
-0.97 / -1.06
Revenue / Forecast
150.04M / 139.31M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
09/2025--/-0.829--/163.52M----Free Sign Up
06/2025-0.97/-1.06150.04M/139.31M+8.49%+7.7%Free Sign Up
03/2025-1.22/-1.3121.46M/121.58M+6.15%-0.1%Free Sign Up
12/2024-1.54/-0.96117.32M/117.69M-60.42%-0.31%Free Sign Up
09/2024-1.34/-1.38103.74M/98.37M+2.9%+5.46%Free Sign Up
06/2024-1.67/-1.3187.2M/86.66M-27.48%+0.62%Free Sign Up
03/2024-1.44/-1.2275M/74M-18.03%+1.35%Free Sign Up
12/2023-2.08/-1.1671.53M/68.83M-79.31%+3.92%Free Sign Up
09/2023-1.32/-1.1957.79M/55.48M-10.92%+4.16%Free Sign Up
06/2023-1.54/-1.2446.01M/40.89M-24.19%+12.52%Free Sign Up

All numbers in USD

Axsome Therapeutics Inc Earnings Call Summary for Q2/2025

  • Axsome beats Q2 forecasts: EPS -$0.97 vs -$1.06 expected, revenue $150M vs $139.31M expected, stock up 4.83% premarket to $108
  • Total product revenues up 72% YoY, Avelity sales surge 84% to $119.6M, Sunosi revenues rise 35%, gross profit margins at 91.49%
  • Company advancing late-stage pipeline programs, including AXS-twelve for narcolepsy and AXS-fourteen for fibromyalgia
  • CEO highlights strong quarter, potential to address conditions affecting over 150M US patients; plans DTC campaign for Avelity in 2025
  • 2025 revenue projected at $602.75M, 2026 at $981.8M; healthy liquidity with 2.03 current ratio despite moderate debt levels
Last Updated: 04/08/2025, 14:08
Read Full Transcript

FAQ

What Is Axsome Therapeutics Inc's Earnings Per Share (TTM)?

The Axsome Therapeutics Inc EPS (TTM) is -5.06.

When Is The Next Axsome Therapeutics Inc Earnings Date?

Axsome Therapeutics Inc will release its next earnings report on 09 Nov 2025.

What Is Axsome Therapeutics Inc’s Revenue Forecasts For Upcoming Quarters?

Axsome Therapeutics Inc’s revenue forecast is 163.52M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.